Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

Gene symbol CD22 Synonyms SIGLEC-2, SIGLEC2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas | PertOrg
Description CD22 molecule

GTO ID GTC0377
Trial ID NCT03185494
Disease Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Follicular Lymphoma
Altered gene CD19|CD22
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment CD19/CD22 CAR-T cells
Generation2nd
PhasePhase1|Phase2
Recruitment statusUnknown
TitleTreatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
Year2017
CountryChina
Company sponsorChinese PLA General Hospital
Other ID(s)CHN-PLAGH-BT-022
Vector information
Vectorretrovirus
ConstructscFv-4-1BB-CD3ζ
Transgene/Inserted geneCD19/CD22-BB-z transgene
Vector production methodPeripheral blood mononuclear cells (PBMC) were collected from the enrolled patients by leukapheresis. The leukapheresis products were washed and cryopreserved. T cells from thawed leukapheresis products were isolated and activated with Dynabeads Human T-Activator CD3/CD28 magnetic beads. PBMCs were cultured in X-VIVO 15 medium supplemented with interleukin (IL)-2. Two days after the initial T cell activation, the T cells were transduced with a lentivirus encoding the CD19/CD22-BB-z transgene. The cells were expanded for an additional 10 days.

Clinical Result

Cohort 1
Administration route infusion
Dosage 1.7~3E6 cells/kg
Donor type Autologous
Pts 6
Age Child, Adult, Older_Adult
Lymph depletion Yes
Outcome 6/6(CR)
Adverse reactions no any CAR-T-related severe events
References PMID: 32245502

Relationship Graph

Overview of Knowledge Graph